NCT07802327Not yet recruiting
PMCF Study of GX-01S CGM in Adults With Diabetes
PROspective Post-Market Clinical Follow-Up (PMCF) Study to Assess the Clinical Benefits of the GX-01S Continuous Glucose Monitoring System in Adult Patients With Diabetes Type 1 and Type 2
Source: ClinicalTrials.gov · Last updated 9 Sept 2026
Brief summary (registry, in English)
This clinical study evaluates the GX-01S Continuous Glucose Monitoring (CGM) System in adults with Type 1 or Type 2 diabetes. CGM systems measure glucose levels continuously throughout the day, providing real-time information that can help patients manage their diabetes more effectively. The study aims to determine whether using the GX-01S CGM System improves glycemic control, as measured by Time in Range (the percentage of time glucose levels stay within a target range). It will also assess safety, treatment satisfaction, quality of life, and ease of use of the device. Participants will wear the GX-01S CGM System for approximately 135 days (about 4.5 months). The first 15 days will be a "blinded" period where participants cannot see their glucose readings, which will be used to establish a baseline. For the remaining 120 days, participants will have full access to their real-time glucose data. Participants will visit the study site at the beginning, Day 15, Day 45, and Day 135 for assessments and questionnaires. The study will enroll 100 adult patients across multiple centers in Europe. Enrollment is expected to begin in September 2026.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 31 Aug 2026
- Start date
- Sept 2026
- Primary completion date
- Feb 2028
- Lead sponsor
- MicroTech Medical（Hangzhou）Co.,Ltd.
- Diseases
- Type 1 diabetes, Type 2 diabetes
- NCT number
- NCT07802327
What you commit to
- Study type: Interventional
- Planned participants: 100
- From Sept 2026 to the primary completion date, Feb 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of any type of rtCGM within 3 months prior to study entry.
- Most recent thyroid function test results abnormal, obtained as part of usual care within the prior 2 years.
- Patient who is currently enrolled in another clinical study, or has recently participated in a clinical study, that could potentially interfere with the outcomes or introduce bias into the results of the current study (as determined by the investigator). This includes studies involving investigational drugs, medical devices, or other interventions that could impact the safety, efficacy, or scientific integrity of this study.
Other illness
- Severe hypoglycemia requiring assistance from another individual within the last 12 months, or seizure or loss of consciousness within the last 3 years.
- History of seizures other than due to hypoglycemia.
- Myocardial infarction or stroke within the past 6 month.
- Presence of a significant medical or psychiatric disorder, or use of a medication that, in the judgment of the investigator, will affect the wearing of sensors, completion of any aspect of the protocol, or increase risk.
- Inpatient psychiatric treatment within the past 6 months.
Lab values
- Estimated glomerular filtration rate (eGFR) \< 30 mL/min obtained within the prior 12 months as part of usual care, or kidney transplant.
- Deemed unsuitable by investigators due to any condition that impacts the reliability of HbA1c measurement.
Other
- Severe hyperglycemia, that required hospitalization within the last 6 months.
- More than one diabetic ketoacidosis (DKA) event in the past year.
- Requirement to undergo magnetic resonance imaging (MRI) during the study period.
- Cognitive difficulties that, in the judgment of the investigator, could impair the individual's ability to follow the protocol or increase risk.
- Currently pregnant, lactating, or planning to become pregnant during the study period (within the past 1 month).
- Patient is unable / unwilling to provide informed consent.
- Patient is unable to comply with the protocol or proposed follow-up visits.
Who the study is looking for
- Patient age is between 18 and 75 years old.
- Patient is clinically diagnosed with diabetes (T1D or T2D), with more than 50% on a stable insulin regimen, defined as no change in the prescribed number of basal insulin administrations per day and less than 10% change in basal total daily insulin dose within 3 months prior to enrollment. Patients not using insulin are considered having a stable treatment regimen if their diabetes management (lifestyle measures and/or non-insulin glucose-lowering medications) has remained unchanged within 3 months prior to enrollment and no treatment intensification is anticipated during the blinded phase.
- Patient has a HbA1c of \>7.5%.
- Patient and investigator signed and dated the informed consent form prior to first sensor placement.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.